Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer.
about
Cardiovascular Health of Patients With Cancer and Cancer Survivors: A Roadmap to the Next LevelAre we ready to predict late effects? A systematic review of clinically useful prediction models.Cardiac Surveillance Guidelines for Trastuzumab-Containing Therapy in Early-Stage Breast Cancer: Getting to the Heart of the MatterTrastuzumab-induced cardiotoxicity: testing a clinical risk score in a real-world cardio-oncology population.An update on cardio-oncology.Individual prediction of heart failure among childhood cancer survivors.Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer.Cardiotoxic heart failure in breast cancer survivors: a concept analysis.Continuous Trastuzumab Therapy in Breast Cancer Patients With Asymptomatic Left Ventricular Dysfunction.Body Surface Area and Baseline Blood Pressure Predict Subclinical Anthracycline Cardiotoxicity in Women Treated for Early Breast Cancer.Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging.Shared Risk Factors in Cardiovascular Disease and Cancer.Risk factors for anthracycline-associated cardiotoxicity.Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancerLong-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial.Benefits of antihypertensive medications for anthracycline- and trastuzumab-induced cardiotoxicity in patients with breast cancer: Insights from recent clinical trials.Adjuvant systemic treatment for elderly breast cancer patients; addressing safety concerns.Cardiovascular prevention in the cancer survivor.Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.Cardiac Complications of HER2-Targeted Therapies in Breast Cancer.Exercise and Aerobic Fitness to Reduce Cancer-Related Cardiovascular Toxicity.Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.Cardiomyopathic Toxicity From Chemotherapy: Is There an Opportunity for Preemptive Intervention?Echocardiographic Assessment of Cardiotoxic Effects of Cancer Therapy.Improving prediction of cardiovascular complications of cancer therapy: what does the future hold?Optimizing cardio-oncology programs for cancer patients.Cardio-Oncology: Progress in Diagnosis and Treatment of Cardiac Dysfunction.Cardio-oncology Related to Heart Failure: Common Risk Factors Between Cancer and Cardiovascular Disease.Cardio-oncology in the older adult.Breast cancer treatment-induced cardiotoxicity.Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.Incidence, time of occurrence and response to heart failure therapy in patients with anthracycline cardiotoxicity.Cardiovascular risk assessment in oncological clinical trials: is there a role for centralized events adjudication?Management of Advanced Heart Failure due to Cancer Therapy: the Present Role of Mechanical Circulatory Support and Cardiac Transplantation.Galician consensus on management of cardiotoxicity in breast cancer: risk factors, prevention, and early intervention.Cardiotoxicity From Human Epidermal Growth Factor Receptor-2 (HER2) Targeted Therapies.Heart failure and breast cancer therapies: moving towards personalized risk assessment.Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1.National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Cardiovascular Disease and Associated Risk Factors Working Group Report.
P2860
Q26864094-732D3AA8-5E23-4DD5-9F39-C6A5693B18B4Q27311616-BBF81892-F037-44E3-97C7-4D9042277BE4Q28075864-4B2FAD7E-1860-439F-960B-447DAEF7CB56Q33840140-940B8746-3148-42CA-AB26-7356710A9406Q34650059-D65135D4-1D85-43E2-8651-7D3E26C2AB28Q35040680-45048483-130D-4EA3-A42C-BE8B74DAA4B8Q35880224-760297B9-8048-485D-B623-A53278A5AFB4Q36002576-9A62A116-D6ED-468F-82CF-24F070138DEEQ36116313-7886890A-395A-4D64-ADD6-E7334C67C160Q36212048-FC7568F2-FA59-4872-ACE4-F2A373AC4FB3Q36451899-FB77E30A-61D9-4B8B-AB10-AAD9DEC70320Q36709155-2A7982DD-6EAE-4CD2-B6AC-D7676F2EC519Q36921775-3EF1CF84-D6AC-49D8-A13F-5A90554793E3Q37131070-E3E640F4-9E73-493D-8E1B-D7B38C923469Q37145885-9395F668-9307-434D-BC46-3017A726DCADQ37166431-C13CB8B7-E920-4880-9B4C-67712C89100BQ37311943-7DC2D743-0141-4FB7-A96B-9B6960FA26A3Q38253136-44F8CC3C-2087-4CBA-A8A8-4F807D54953FQ38338228-6F9AC659-B3D2-4E3F-AACC-8043842A83D8Q38678021-AE3D8E98-9DF3-4650-B2B1-AAE31EE0AEC4Q38791220-7DA77878-7E78-40E4-A9EC-76A3A33EB200Q38834995-603DEDA7-FCD7-49A2-8C1A-93078A8BA74DQ38877306-00363DD1-A051-4773-BD6A-1788001E6C71Q38904284-59954782-6B50-4062-A288-C9307525CE78Q38938410-51873160-C5F5-4F8F-B813-2901BEF16A77Q38978030-20D681B7-BB86-4FD5-9B79-33F37211C34EQ38982311-2508971C-0456-4A01-8D53-C7231D33996BQ39078275-404BDF62-A5C1-4B59-9774-78ACB77C9F05Q39171512-E21887F1-1BE0-48FA-9A7D-5E8D5A134F89Q39303131-14A67479-79C9-4D0D-9727-2686B45C9772Q39428826-43D8FC86-D364-48DC-884E-DDBD3161C767Q40353199-4877241F-2704-44A3-820B-B7ABD21FDB16Q40500474-5D596F7B-462C-4E05-B85F-AD52044333FBQ41053984-F1181ADC-792C-4531-89BC-43078BB555E8Q41243586-FE985E65-9E36-484C-AD01-88FE4C647286Q41288150-47C59636-4B33-487A-8BC4-76A7CADFC488Q42373758-1AD77FA8-A1A6-4A1B-9043-7530B4F74EF4Q42406335-4DA669BE-4374-42F5-A91F-FCE8AD2634B5Q45073135-77F5F878-9DA9-4EFA-988C-8ED19AFECBC6Q46181268-A00A8F98-10DB-4F8B-AD14-35E5A9DA80B4
P2860
Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 February 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Risk prediction model for hear ...... mab therapy for breast cancer.
@en
Risk prediction model for hear ...... mab therapy for breast cancer.
@nl
type
label
Risk prediction model for hear ...... mab therapy for breast cancer.
@en
Risk prediction model for hear ...... mab therapy for breast cancer.
@nl
prefLabel
Risk prediction model for hear ...... mab therapy for breast cancer.
@en
Risk prediction model for hear ...... mab therapy for breast cancer.
@nl
P2093
P2860
P356
P1476
Risk prediction model for hear ...... mab therapy for breast cancer.
@en
P2093
Cary P Gross
Ghideon Ezaz
Jersey Chen
Jessica B Long
P2860
P304
P356
10.1161/JAHA.113.000472
P577
2014-02-28T00:00:00Z